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 ORIGINAL ARTICLE 
Early prediction of pathological response in locally advanced 
rectal cancer based on sequential  18 F-FDG PET
 MATHIEU  HATT 1,2 ,  RUUD VAN  STIPHOUT 1 ,  ADRIEN LE  POGAM 2 , 
 GUIDO  LAMMERING 1 ,  DIMITRIS  VISVIKIS 2 &  PHILIPPE  LAMBIN 1  
 1 Department of Radiation Oncology (MAASTRO), GROW Research Institute, Maastricht, The Netherlands 
and  2 INSERM, UMR 1101 LaTIM, Brest, France 
 Abstract 
 Background. The objectives of this study were to investigate the predictive value of sequential  18 F-FDG PET scans for 
pathological tumor response grade (TRG) after preoperative chemoradiotherapy (PCRT) in locally advanced rectal cancer 
(LARC) and the impact of partial volume effects correction (PVC).  Methods. Twenty-eight LARC patients were included. 
Responders and non-responders status were determined in histopathology. PET indices [SUV max and mean, volume and 
total lesion glycolysis (TLG)] at baseline and their evolution after one and two weeks of PCRT were extracted by deline-
ation of the PET images, with or without PVC. Their predictive value was investigated using Mann-Whitney-U tests and 
ROC analysis.  Results. Within baseline parameters, only SUV mean was correlated with response. No evolution after one 
week was predictive of the response, whereas after two weeks all the parameters except volume were, the best prediction 
being obtained with TLG (AUC 0.79, sensitivity 63%, specifi city 92%). PVC had no signifi cant impact on these results. 
 Conclusion. Several PET indices at baseline and their evolution after two weeks of PCRT are good predictors of response 
in LARC, with or without PVC, whereas results after one week are suboptimal. Best predictor was TLG reduction after 
two weeks, although baseline SUV mean had smaller but similar predictive power. 
 Preoperative radiochemotherapy (PRCT) is now 
considered a standard treatment for patients diag-
nosed with locally advanced rectal cancer (LARC). 
A signifi cant tumor downsizing and downstaging, as 
well as a reduction of the risk for local recurrence 
and longer survival have been observed as a result of 
PRCT [1 – 3]. Within this context,  18 F-FDG PET 
imaging has been demonstrated as an interesting 
predictive tool [4]. Indeed, correlations between 
the pathological tumor response after PRCT and the 
standard uptake value (SUV) decrease within the 
tumor have been demonstrated in several studies 
[5 – 9]. In most of these studies, the SUV evolution 
between the baseline positron emission scan (PET) 
scan and the one acquired before surgery was cor-
related with the tumor regression grade (TRG) [5 – 9]. 
However, allowing for earlier prediction of the 
response is of higher interest for the clinical practice, 
since it might enable modifi cations of the treatment 
protocol [10]. A few studies have investigated the 
early prediction of the pathological tumor response 
based on  18 F-FDG PET imaging during PRCT 
[8,9]. Cascini et  al. showed that changes in the met-
abolic activity of the tumor, measured as early as 
15 days after the start of PRCT, were predictive for 
response [8]. More recently, Janssen et  al. have exam-
ined three different time points of  18 F-FDG PET 
imaging during PRCT, in order to defi ne the optimal 
time for early prediction [9]. In this study  18 F-FDG 
PET scans at baseline, as well as at 8 and 15 days 
during PRCT were carried out and it was found that 
the best predictive factor of TRG was the SUV max 
response index (RI, defi ned as the percent evolution 
relative to the pretreatment value) at 15 days. All 
these studies have considered SUV measurements 
(max and/or mean) only. It has been demonstrated 
recently in several studies and various malignancies 
that other  18 F-FDG PET derived parameters more 
fully characterizing tumors on a functional level can 
have statistically higher predictive value than SUV 
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[10 – 17]. These include metabolically active tumor 
volume (MATV, defi ned as the tumor volume as it 
can be seen and delineated on a PET image) [11] 
and total lesion glycolysis (TLG, multiplying MATV 
and its associated mean SUV) [12]. In addition, 
some of these studies demonstrated that response 
could be predicted by extracting these parameters 
from the pretreatment scan only, therefore poten-
tially eliminating or reducing the need for sequential 
scans during treatment. Such results have been 
presented within the context of locally advanced 
esophageal cancer (LAEC) [11,13], non-Hodgkin 
lymphoma [14], pleural mesothelioma [15] and 
cervix and head and neck cancers [16], whereas 
confl icting results have been recently obtained in 
rectal cancer [17,18]. Finally, most of these studies 
have considered the evolution of PET derived 
parameters without partial volume effects (PVE) 
correction (PVC). This may lead to biased results 
especially if MATVs change size and/or shape during 
treatment. The current study was therefore con-
ducted retrospectively on the cohort previously 
imaged [9] with the following objectives: 1) deter-
mine the predictive value of baseline  18 F-FDG PET 
derived parameters; 2) investigate the evolution of 
these parameters during treatment and their associ-
ated predictive value; and 3) investigate the impact 
of PVC on these results. 
 Material and methods 
 Patients 
 This study consisted of a retrospective analysis of 
a cohort of 28 patients (see Table I) diagnosed with 
non-metastasized LARC previously recruited in a 
prospective imaging study [9] approved by the 
medical ethics committee and for which all patients 
gave written informed consent before entering the 
study. Although all tumors may not strictly speaking 
be considered as locally advanced according to stag-
ing, none of the patients could be resected immedi-
ately because of the high risks of differentiation, 
bulkiness, and size and location of the tumor. They 
were therefore all treated with the same PCRT 
protocol as recommended for LARC patients. All 
patients underwent PRCT (28 fractions of 1.8 Gy, 
5 fractions a week, and concomitant capecitabine, 
825 mg/m 2 , twice a day), followed by surgery (total 
mesorectal excision). Patients underwent  18 F-FDG 
PET/CT scans at baseline, and on Days 8 and 15 of 
treatment. From here onwards, these scans will be 
denoted as PET i , with i from 1 to 3. 
 18 F-FDG PET/CT acquisitions 
 The protocol was designed to ensure robust SUV 
measurements across all three time points. Patients 
received an intravenous injection of FDG after a 
minimal fasting period of 6 h, with the activity nor-
malized for the weight of the patient as follows: 
 (weight [kg]   4    20) [MBq] 
 After an uptake period of exactly 60 min, all acquisi-
tions were carried out on a Siemens Biograph 40 
TruePoint scanner (Siemens Medical, Erlangen, 
Germany) with a spatial resolution of approximately 
6 mm at full-width-at-half-maximum. Listmode 
data of the abdominal region were acquired in three-
dimensional (3D) mode with scatter, decay, and 
computed tomography (CT)-based attenuation cor-
rections, and 5 min per bed position. Images were 
reconstructed using Fourier rebinning and 2D 
OSEM (four iterations, eight subsets) with voxel 
size 4.1   4.1   3 mm 3 without post-fi ltering. 
 Pathological tumor response grade (TRG) 
 The ground-truth of tumor response to therapy 
was determined in histology since all patients under-
went total mesorectal excision. As proposed by 
Mandard et  al. [19], TRG for each tumor was deter-
mined by an experienced pathologist blinded to the 
imaging data as follows: TRG 1, complete tumor 
response; TRG 2, residual cancer cells scattered 
through fi brosis; TRG 3, an increased number 
of residual cancer cells, with predominant fi brosis; 
TRG 4, residual cancer outgrowing fi brosis; and 
TRG 5, no regressive changes within the tumor. 
Tumors were subsequently grouped into responders 
(TRG 1 – 2) and non-responders (TRG 3 – 5). 
 Table I. Patients ’  characteristics. 
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 Partial volume effects correction 
 All PET images were corrected for PVE using an 
iterative deconvolution method previously validated 
on simulated and clinical datasets [20]. This approach 
iteratively estimates the corrected voxels values 
through Lucy-Richardson deconvolution [21,22] 
with prior knowledge (within    1 mm, as it has been 
shown that a 1 mm error in the PSF led to a negli-
gible impact on measured SUVs [23]) of the scan-
ner ’ s Point Spread Function (PSF), assumed to be 
spatially invariant in the fi eld of view. In this study 
the tumors were all in the exact same body region 
and this assumption has therefore no signifi cant 
impact on the applied correction on a patient-by-
patient comparison basis. Wavelet-based denoising 
was incorporated using Bayeshrink fi ltering [24], 
applied to the residual within each iteration of 
the deconvolution process. This allows using a suf-
fi cient number of iterations to correct for PVE 
without signifi cant noise addition. This methodology 
is voxel-based and therefore does not assume homo-
geneous regional radiotracer distributions for the 
tumor and/or surrounding background. 
 Investigated parameters and analysis 
 All parameters were extracted from the original 
(PET 1 – 3 ) and PVE corrected (PET 1 – 3 
PVC ) 
images, denoted from here onwards param 1 – 3 and 
param 1 – 3 
PVC respectively. For each patient, the tumor 
was identifi ed on each PET i images by a nuclear 
physician with more than 10 years experience and 
subsequently semi-automatically isolated from the 
bladder in a 3D region of interest (ROI) using an 
in-house software. This ROI, containing only the 
MATV and its surrounding background, was auto-
matically transferred to the corresponding corrected 
PET i 
PVC image. MATV were subsequently delin-
eated on both uncorrected and corrected images 
using an implementation of the Fuzzy Locally Adap-
tive Bayesian (FLAB) automatic algorithm [25] 
in the same software. The FLAB approach allows 
automatic tumor delineation by computing a prob-
ability of belonging to a given  “ class ” , e.g. tumor 
or background, for each voxel within the 3D ROI. 
This probability is calculated by taking into account 
the voxel ’ s intensity with respect to the statistical 
distributions (characterized by their mean and vari-
ance) of the voxels in the various regions of the 
image, as well as its spatial correlation with neighbor-
ing voxels in 3D. This approach has been validated 
on simulated and clinical datasets for accuracy, 
robustness and reproducibility, on both homoge-
neous and heterogeneous MATVs [25 – 27]. 
 SUV max , and SUV mean as well as the MATV and 
the TLG were automatically calculated from these 
delineations. MATV was defi ned as the sum of all 
voxels contained in the FLAB delineated volumes 
multiplied by the volume of a voxel (50.43 mm 3 ). 
TLG was determined by multiplying the MATV and 
its associated SUV mean . Response indices (RIs) cor-
responding to one (RI 2 ) and two (RI 3 ) weeks were 
calculated as the percentage evolution with respect 
to the baseline value (PET 1 ) as follows: RI n   (param n –
 param 1 )/param 1   100 for n    2 and 3. Similarly, 
RI 2 – 3 
PVC were calculated using the parameters 
extracted from PET 1 – 3 
PVC images. 
 Figure 1 illustrates for a non-responder 
(Figure 1A) and a responder (Figure 1B) the base-
line scan and the scan after two weeks, with the delin-
eation of the tumor on both scans. 
 Statistical analysis 
 Statistical analyses were performed using Medcalc TM 
(MedCalc Software, Belgium). All quantitative val-
ues were expressed as means   standard deviations 
(SD) and ranges (minimum – maximum). Binary 
response status based on TRG classifi cation (1 – 2 vs. 
3 – 5) was correlated with baseline values (param 1 ) as 
well as RI 2 – 3 for early sequential scans (PET 2 – 3 ) 
using a Mann-Whitney U-test. For the parameters 
that were found to be signifi cantly correlated with 
response, the predictive performance regarding the 
identifi cation of non-responders was evaluated using 
ROC analysis. Area under the curve (AUC), along 
with the best compromise between sensitivity and 
specifi city were reported, as well as results associated 
with a specifi city of 100%, corresponding to the 
clinical goal of identifying non-responders without 
erroneously identifying any of the responders. 
For RI 2 – 3 , only cut-off values above   30% or 
below 30% were considered. This constraint was 
applied because the reproducibility (or test-retest 
assessment) of the PET derived parameters (both 
SUV and volume-based measurements) under 
investigation here has been previously determined 
to be at such upper and lower limits [27]. Thus char-
acterization of response (or disease progression) 
based on evolution of PET derived indices must 
take into account such reproducibility limits. All 
tests were two-sided and p-values below 0.05 were 
considered statistically signifi cant. 
 Results 
 Statistics for baseline and evolution of all derived 
parameters (with or without PVC) are given in 
Table II. Results of Mann-Whitney U-tests and 
subsequent ROCs analyses are provided in Supple-
mentary Table I online at http://www.informa
healthcare.com/doi/abs/10.3109/0284186X.2012. 
702923 and Table III, respectively. 
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 Figure 1.  Illustration of the baseline scan (on the left) and the scan at 2 weeks (PET3, on the right) for (A) a responder and (B) a non-
responder. The green contour is the FLAB delineation. 
 Pathologic tumor response 
 Six tumors were characterized by complete patho-
logic response (TRG 1) and six had residual cancer 
cells (TRG 2). Nine, six and one tumors were 
classifi ed as TRG 3, 4 and 5, respectively (Table I). 
There were therefore 12 responders (43%) and 
16 non-responders (57%). 
 Predictive value of baseline parameters 
 Without PVC .  Pretreatment SUV measurements 
were all normally distributed, with SUV max1 and 
SUV mean1 values for the cohort of 14.9    5.2 and 
8.0    2.8, respectively. On the other hand, MATV 1 
and TLG 1 were not normally distributed. Median 
MATV 1 and TLG1 values were 23 cm 
3 and 181 g, 
respectively. Most volumes were within the range 
of 10 – 40 cm 3 , with fi ve tumors above 100 cm 3 . 
 Table II. Baseline values and evolution (RIs) of each PET derived parameter with respect to baseline values. 
Parameter
Baseline value median   SD 
(mean, min, max)
RI 2 (%) median   SD 
(mean, min, max)
RI 3 (%) median   SD 
(mean, min, max)
SUV max 13.9    5.2 (14.9, 6.6, 26.7)   18    39 (  12,   63,   155)   32    25 (  31,   73,   47)
SUV max 
PVC 21.2    9.7 (23.8, 10.2, 49.3)   20    41 (  15,   59,   165)   43    27 (  38,   75,   47)
SUV mean 7.8    2.8 (8.0, 3.7, 13.9)   20    36 (  11,   59,   138)   29    25 (  28,   66,   54)
SUV mean 
PVC 10.2    4.0 (10.3, 4.5, 20.8)   22    37 (  12,   56,   153)   28    24 (  29,   67,   42)
MATV 23    79 (49, 2, 397)   18    22 (  15,   51,   51)   36    29 (  32,   80,   42)
MATV PVC 19    76 (45, 2, 378)   15    22 (  15,   51,   39)   32    28 (  32,   78,   37)
TLG 181    473 (345, 10, 2235)   35    45 (  22,   75,   137)   57    37 (  48,   86,   68)
TLG PVC 196    518 (379, 13, 2385)   34    41 (  24,   75,   130)   59    33 (  50,   88,   51)
 Responding tumors were characterized by 
higher baseline SUV (SUV max1 15.6    3.7 and 
SUV mean 9.0    2.3) than non-responding ones 
(SUV max1 12.5    5.8 and SUV mean 6.4    2.9). The 
difference was not signifi cant for SUV max (p    0.06) 
contrary to SUV mean (p    0.02), with an associated 
AUC of 0.75 (Table III) leading to perfect specifi city 
(100%) but an associated sensitivity of 50% for 
a cut-off value of 6.1. 
 No correlation between response and MATV 1 
or TLG 1 was found (p    0.1), distributions of these 
parameters among responders and non-responders 
being largely overlapped (Table II). 
 With PVC .  Pretreatment SUV max and SUV mean 
increased by    57    23% and    27    10% after cor-
rection, to 21.2    9.7 and 10.2    4.0, respectively. 
On the other hand, MATV 1 
PVC were systematically 
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smaller with however a small difference of only 
12    6% (range 3% to 24%). Resulting from a 
combination of smaller MATV and higher SUV mean , 
TLG 1 
PVC increased by   11    7% (range 1% to 
  31%). The increase of SUV mean was strongly cor-
related with MATV (r    0.7, p    0.0001) whereas 
increase of SUV max was not (r    0.5). Despite these 
absolute values increase, the differences between 
responding and non-responding tumors were not 
signifi cantly altered by PVC. SUV max1 
PVC still did 
not signifi cantly separate responding from non-
responding tumors (p    0.07) whereas SUV mean1 
PVC 
allowed similar differentiation (p    0.02), and no 
correlation with response was found for MATV 1 
PVC 
and TLG 1 
PVC (p    0.2). 
 Regarding ROC analysis, AUCs and associated 
optimal sensitivities/specifi cities with PVC were mostly 
similar as without correction. For SUV mean1 
PVC , 
AUC increased from 0.75 to 0.76, although it led to 
a reduced sensitivity (44% instead of 50%) with the 
same specifi city of 100% (Figure 2A). 
 Evolution of parameters during PRCT 
and associated predictive value 
 Without PVC .  There was a global trend to decreasing 
MATV and associated uptake of the tumors during 
PRCT across the cohort of patients, with further 
reduction at 15 days (Table II). However, these PET 
parameters were also found to be increasing for 
some patients (Table II), especially after eight days. 
The lowest decreases at eight days were observed 
for MATV and SUV max (mean 12% and 15%, 
median 18% for both) whereas the largest decrease 
was observed for TLG with a mean of 22% (median 
35%). Decrease was systematically larger at 15 
days, with for instance 48 mean TLG decrease 
(median 57%). 
 On the one hand, none of the RI 2 s were 
statistically different between responders and non-
responders, except for SUV mean (6    44% vs. 
25    12%, p    0.04) and TLG (18    53% vs. 
37    15%, p    0.03). On the other hand, RI 3 s of 
 Table III. Predictive value of each parameter baseline values and RIs using ROCs analysis. Only 
parameters for which a signifi cant correlation was found [see appendix, to be found online, at 













SUV max RI 3 (%) 0.77   43 88 58 31   16
SUV max 
PVC RI 3 (%) 0.73   33 50 83 13   5
SUV mean PET 1 0.75 6.1 50 100 50 6.1
RI 2 (%) 0.73   31 88 33 50   10
RI 3 (%) 0.79   34 81 67 31   11
SUV mean 
PVC PET 1 0.76 7.3 44 100 44 7.3
RI 2 (%) 0.77   33 81 25 50   8
RI 3 (%) 0.75   42 88 58 19   8
TLG RI 2 (%) 0.75   34 56 67 56   23
RI 3 (%) 0.79   53 63 92 38   37
TLG PVC RI 2 (%) 0.70   34 56 50 44   18
RI 3 (%) 0.78   54 63 92 31   38
 Figure 2. ROCs examples for prediction of non-responders (n    16), using (A) SUV mean with or without PVC, (B) TLG and SUV mean 
RI 3 , and (C) logistic regression combining baseline MATV and SUV mean values and their evolution after 8 and 15 days, with and without 
PVC. 
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all the parameters except MATV were statistically 
different between responders and non-responders, 
especially for TLG and SUV mean (p    0.009). 
 According to ROCs analysis, RI 2 s of neither 
SUV mean nor TLG (the only two parameters for 
which there was a statistical difference at eight 
days between responders and non-responders) 
allowed satisfactory prediction of TRG. With an 
AUC of 0.73, the optimal cut-off value above 30% 
change (31%) for SUV mean was associated with 
a sensitivity of 88% but a specifi city of only 33%. 
RI 2 of TLG led to an AUC of 0.75 and much lower 
sensitivity (56%) but higher specifi city (67%) with 
a cut-off value of 34%. At eight days, 100% 
specifi city could be achieved only using too low 
cut-off values (10% only for SUV mean , and 23% 
for TLG) and at the cost of reduced sensitivity for 
SUV mean (50%). 
 Predictive performance improved at 15 days with 
higher sensitivities/specifi cities for all parameters. 
For SUV max , a 43% RI 3 cut-off value was associated 
with 88% sensitivity and 58% specifi city, whereas a 
34% RI 3 for SUV mean led to 81% sensitivity and 
67% specifi city. Reduction of TLG using a RI 3 
cut-off value of 53% led to lower sensitivity 
(63%) but higher specifi city (92%) (Figure 2B). At 
15 days, maximizing specifi city was associated with 
low RI 3 cut-off values (11 and 16% for SUV mean 
and SUV max ), except for TLG for which the cut-off 
value was 37%, with however a sensitivity of 
only 38%. Sensitivities associated with 100% speci-
fi city were also between 30% and 40% for the other 
para meters. 
  .  Evolution of the parameters after 8 and 
15 days was not signifi cantly altered by PVC, with 
very similar values of RIs for all parameters (see 
Table II). PVC had therefore no impact on the sta-
tistical difference between RIs of responders and 
non-responders. After correction, the RI 2 s still did 
not allow statistical differentiation between respond-
ers and non-responders for most parameters, except 
for TLG and SUV mean which was already the case 
without PVC. Similarly, all the RI 3 s except MATV 
were still able to statistically differentiate the non-
responders from the responders after PVC, but the 
differentiation was signifi cantly neither improved nor 
reduced. 
 Similarly, ROCs results were not signifi cantly 
altered by PVC, although AUCs varied by up to 
   0.05. Sensitivities and specifi cities corresponding 
to optimal cut-off values on the other hand were 
in a few cases signifi cantly modifi ed. For example, 
the sensitivity associated with RI 3 of SUV max 
was decreased after PVC from 88 to 50%, with 
an increase of specifi city from 58 to 83%. Similar 
changes were observed for the other parameters at 
both 8 and 15 days, without nonetheless signifi cantly 
reduce or increase the predictive performance of the 
parameters. 
 Discussion 
 Neither the predictive value of baseline PET 
images nor the one of PET features more fully 
describing tumors (MATV, TLG) has been exten-
sively determined yet within the context of PCRT 
early prediction in rectal cancer. Melton and col-
leagues found in 21 LARC patients that the reduc-
tion of PET-based parameters (MATV, TLG and 
SUV) between baseline and four to six weeks 
after treatment was correlated with pathological 
response [17], but they did not investigate the value 
of baseline parameters. More recently, Chennupati 
and colleagues did not fi nd a correlation between 
pathological response and SUV max or MATV mea-
surements at baseline or reduction after treatment 
in a cohort of 35 LARC patients, but they did 
not investigate the value of parameters reduction 
during the treatment [18]. Janssen and colleagues 
demonstrated that the reduction of SUV max after 
two weeks was a good predictor of response, but 
they did not investigate other PET parameters 
beyond SUV mean or their baseline predictive value 
[9]. None of these studies investigated the impact 
of PVC. To the best of our knowledge, the current 
study is the fi rst investigation on a homogeneous 
LARC cohort including the impact of PVC, four 
PET derived parameters (SUV max , SUV mean , MATV, 
TLG), and three (baseline and after one and two 
weeks)  18 F-FDG PET scans during PCRT. 
 On the one hand, contrary to results in LAEC 
[10], neither the baseline MATV nor the derived 
TLG were signifi cantly associated with response. On 
the other hand, some of the baseline parameters were 
of predictive value, such as higher SUV mean being 
associated with responding tumors (p    0.02), and 
allowed prediction of the non-responders with a 
specifi city of 100% but a limited sensitivity of 50%. 
A similar trend was observed with SUV max , although 
without reaching statistical signifi cance (p    0.06). 
 Overall, response was associated with higher 
decrease of the  18 F-FDG PET derived indices within 
the fi rst two weeks of PCRT, especially SUV mean 
and TLG (p    0.01), although this decrease was 
a more effi cient predictive factor after two weeks 
than one, in line with previous fi ndings [9]. First, 
none of the parameters ’ RI 2 s except for SUV mean and 
TLG were signifi cantly correlated with TRG. 
Second, an important constraint was that cut-off val-
ues of RI 2 – 3 s had to be larger than    30%, because 
of the upper and lower reproducibility limits of such 
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PET derived measurements [27]. However, mea-
sured RI 2 – 3 s were often within this range, especially 
after one week, although it was still the case even 
after two weeks. This may constitute one of the 
major limitations of early PET based response pre-
diction, and the reproducibility of PET acquisitions 
clearly need to be improved in that regard. On 
the one hand, according to ROCs analysis, the reduc-
tion of SUV mean after two weeks was associated with 
an AUC of 0.79, a 100% specifi city and 31% sensi-
tivity associated with a RI 2 cut-off value of 11%, 
which is too low with regard to the reproducibility 
limits, as it is the case for all other parameters. 
The only exception was TLG: a 37% RI 3 cut-off 
value led to 100% specifi city and 38% sensitivity, 
whereas a 53% cut-off value led to the best 
compromise of 63% sensitivity and 92% specifi city. 
 Usually, higher SUVs are associated with more 
aggressive tumors, and therefore may be potentially 
more resistant. However according to our results, 
responding tumors were found to have higher initial 
SUVs. This can be associated with the fact that they 
were also the ones exhibiting the highest uptake 
decrease during treatment. In addition, the tumors 
that were classifi ed as non-responders based on the 
RI 3 of TLG (specifi city 100%, sensitivity 38%) are 
almost the same as those classifi ed as non-responders 
based on their baseline mean SUVs (specifi city 
100%, sensitivity 50%). Therefore waiting for two 
weeks did not signifi cantly (p    0.05) improve pre-
diction of response in this context when maximizing 
specifi city, despite increased overall AUCs, which 
is a new result with respect to previous fi ndings 
that only investigated the predictive value of RIs and 
not absolute baseline values [9]. 
 The classifi cation could be further improved 
using logistic regression of several parameters such 
as baseline MATV and SUV mean values and their 
evolution at 8 and 15 days, resulting in an AUC of 
0.88, with a sensitivity and specifi city of 88% and 
83% respectively, whereas a specifi city of 100% was 
associated with 50% sensitivity (Figure 2C). Similar 
results were obtained with PVC (AUC 0.92, 92% 
specifi city and 81% sensitivity, 56% sensitivity 
associated with 100% specifi city). However, such 
weighted model combining more than one parameter 
on 28 patients only is likely to be over fi tted to the 
data and would require validation on a larger cohort. 
 Regarding PVC, despite signifi cant impact on 
the absolute values (except for MATV), it had 
limited impact on the predictive value of the 
parameters. Similar results regarding the impact of 
PVC on baseline predictive value were obtained 
for baseline prediction of chemoradiotherapy res-
ponse in LAEC [28]. This is the fi rst study however 
investigating the PVC impact on the predictive value 
of sequential scans. This lack of impact may be 
explained by the fact that although the tumor 
volumes signifi cantly shrunk during the fi rst two 
weeks of PCRT (36    29% after two weeks), their 
volume were still large (mean 36 cm 3 ). Since PVE 
are signifi cant for volumes below 10 – 15 cm 3 , PVC 
impact should be investigated for the follow-up 
of tumors exhibiting larger changes and/or smaller 
volumes. 
 Some limits of this study have to be emphasized. 
It is fi rst limited by its retrospective nature and 
the small number of patients, which led to group the 
fi ve different classifi cations of TRG into responders 
and non-responders. Investigation of other response 
classifi cation such as complete regression (TRG1) 
vs. non-response (TRG 2 – 5) or all fi ve TRG statuses 
should be conducted in larger prospective studies 
in order to validate our preliminary results. Finally, 
the TRG classifi cation, although it constitutes the 
best measurement of tumor response available, was 
determined by one pathologist only. 
 Conclusion 
 Our results in this preliminary study suggest that 
early prediction of tumor response to PRCT in 
rectal cancer using sequential  18 F-FDG PET 
scans is challenging due to limited reproducibility of 
PET imaging, especially after one week that was 
found to be suboptimal in both robustness due to 
small evolutions of the parameters and accuracy 
with no correlation with response. The best compro-
mise between accuracy and robustness of prediction 
was obtained by considering the reduction of total 
lesion glycolysis after two weeks of PCRT, with a 
sensitivity of 63% and specifi city of 92%, although 
the improvement over baseline absolute mean SUV 
prediction (specifi city 100%, sensitivity 50%) was 
not signifi cant. Finally, partial volume effects correc-
tion had no impact on the predictive value of neither 
the baseline absolute values nor their evolution 
during treatment. The results of this study require 
validation in a larger cohort allowing consideration 
of less restrictive response measures. 
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